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Melanoma is a devastating disease frequently encountered within both veterinary and 
human medicine. Melanocytic tumours are relatively common in dogs and represent 4 to 7% 
of all canine neoplasms. It is the most common malignant neoplasm of the oral cavity and 
the second most frequent subungual neoplasm. Classically, body location is one criteria 
used to establish a prognosis of these tumours (Martínez et al., 2011; Smith et al., 2002). 
Cutaneous canine melanocytic lesions are usually benign. However, the canine 
oropharyngeal, uveal, and mucocutaneous neoplasms are aggressive and have high 
metastatic potential (Marino et al., 1995; Smith et al., 2002; Spangler & Kass, 2006). 
In other animals species melanocytic tumours were also seen, but in cats it is not as common 
and carries a poor prognosis (Dorn&Priester, 1976; Goldschmidt, 1985). In white or gray 
horses melanoma is very common, considered almost inevitable (Johnson, 1998; Valentine, 
1995). In pigs, melanoma is very frequent in some breeds, as Sinclair (Berkelhammer&Hook, 
1980; Hook et al., 1982; Misfeldt & Grimm, 1994).  
Generally, cutaneous melanoma in domestic animals does not share the same degree of 
diversity described in the medical literature. Canine cutaneous melanoma can be either 
benign (melanocytoma) or malignant (melanoma) and are most common in older animals 
with darker coats. The benign form is often referred to as melanocytic nevus or 
melanocytoma, and is well<defined, firm, dome<shaped, with less than 2 cm in diameter and 
mobile. Malignant melanomas are less frequent in the skin and appear ulcerated with a 
rapid grow. Most oral and mucocutaneous (except eyelid) and 50% of nail bed (subungual) 
melanomas are malignant (Smith et al., 2002) 
Unlike humans, dogs do not seem to develop malignant melanomas due to exposure to 
ionizing solar radiation. With the exception of gray horses, malignant transformation of 
benign lesions is very uncommon in animals, and most melanomas are believed to arised 
“” from melanocytes in the epidermis, dermis, ocular epithelium, and oral epithelium 
(Conroy, 1967; Smith et al., 2002). However, little is known about initiation of most animal 
melanomas. Breed and familial clustering in domestic animals suggest that genetic 









be critical to initiation of many of these tumours (Goldschmidt, 1985; Smith et al., 2002). 
Conroy described two canine cases of melanoma that arose from junctional or dermal 
pigmented nevi (hamartomas), although in neither case was metastatic behavior observed 
(Conroy, 1967). There is a single report of a primary melanoma in the skin of a dog that 
originated from a subcutaneous melanocytoma (Mulligan, 1961).  
Cutaneous melanoma is the group of melanocytic lesions that constitute the big challenge to 
pathologist. The majority of the cases are benign but can be find malignant melanomas with 
elevated aggressiveness. Mitotic rate is highly predictive of the degree of malignancy and a 
mitotic rate of less than 3 per 10 high<power fields is strongly associated with benign 
behavior (Smith et al., 2002). Additional analysis by flow cytometry has shown a correlation 
between DNA ploidy and malignancy (Bolon et al., 1990). In the last years, several 
prognostic factors related to proliferation (Laprie et al., 2001; Roels et al., 1999), angiogenesis 
(Mukaratirwa et al., 2006; Taylor et al., 2007), apoptosis (Roels et al., 2001), and others have 
been investigated. 
The incidence of melanocytic lesions is increasing among canine population. Canine 
malignant melanoma could have an aggressive behavior, metastasize early in the course of 
the disease and is resistant to most current therapeutic regimens. The role of a vaccine and 
the search of novel therapeutic tools are essential in the fight against this devastating 
disease. Furthermore, the similarities between human and canine melanoma make 
spontaneous canine melanoma an excellent disease model for studying the correspondent 
human disease (Bergman et al., 2006; Smith et al., 2002; von Euler et al., 2008). 
Inflammation in tumour stroma greatly influences its development. In human cancer it has 
been described that tumour associated macrophages (TAMs) may promote tumour cell 
invasiveness and potentiate metastatic diffusion. Among the various inflammatory 
mediators generated by TAM, assume particular relevance the arachidonic acid metabolites, 
which are known to influence several biological responses involved in tumour progression, 
such as inflammatory and immune reactions, haemostasis and angiogenesis. Although the 
scientific evidence of an association between TAM and histological aggressiveness in human 
melanoma (Bianchini et al., 2007; Brocker et al., 1987), in the dog there are no studies 
concerning this subject.  
Cyclooxigenase (<1 and <2) are isoenzymes that promote the transition of arachidonic acid in 
to different prostanoids. These isoenzymes are also the main targets of the NSAIDs (non 
steroid anti<inflammatory drugs). Several studies have been suggested the potential role of 
NSAID blocking particularly cyclo<oxygenases<2 (Cox<2) in the prevention and treatment of 
malignant tumours in humans (Cerella et al., 2010; Dubois et al., 1998). In dogs, there are 
evidences of a strong relationship between Cox<2 expression and malignancy in several 
types of cancers (bladder, skin, intestinal, mammary, bone, nasal) (Mohammed et al., 2004; 
Queiroga et al., 2007). Cox<1 and Cox<2 expression in canine melanocytic lesions has been 
recently published by the authors, describing that Cox<2 expression was restricted to the 
malignant melanoma group, being found in 11 of the 20 cutaneous malignant melanomas, in 
all oral malignant melanomas and in one of two ocular malignant melanomas analyzed. 
Authors also found that Cox<2 labeling was particularly intense in the more aggressive oral 
tumours (Pires et al., 2010). In human melanoma, Cox<2 has been implied in tumour 
progression (Chwirot&Kuzbicki, 2007; Kuzbicki et al., 2006). 
The aims of the present work were: a) to describe, the number and the distribution of TAMs 
in canine melanocytic lesions; b) to investigate associations between TAMs and several 
clinicopathological characteristics; c) investigate the possible association between Cox<2 










Thirty seven melanocytic tumours, obtained from the UTAD Histopathology Laboratory 
archives were included. For the histopathologic study, 4<Hm<thick tissue sections were 
stained with the hematoxylin and eosin with and without blanching by incubation in 0,25% 
potassium permanganate for 30–60 minutes, depending on the amount of pigment and then 
by incubation in 0,1% oxalic acid for 5–8 minutes. Each sample was re<examined by two 
independent pathologists (IP and JP) in order to confirm the diagnosis, according to the 
World Health Organization International Histological Classification of Tumours of 
Domestic Animals criteria (Goldschmidt et al., 1998).  
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The following clinicopathological features were evaluated: histological type<melanocytoma 
(benign), melanoma (malign); presence of ulceration; presence of necrosis; mitotic index; 
nuclear grade; degree of pigmentation, presence of aberrant tumoural cells; stroma; and 
tumoural vascular invasion. Mitotic index was calculated by counting all the mitosis present 
in 10 high power fields (HPF) (400x): mitotic index I (<3 mitosis in 10 HPF); mitotic index II 
(3–5 mitosis in 10 HPF) or mitotic index III (>5 mitosis in 10 HPF). For nuclear grade, the 
following grades were defined: (i) nuclear grade I when the nuclei had minimal variations in 
their shape and size compared to normal nuclei; (ii) nuclear grade II consisted of moderate 
alterations of nuclear shape; and (iii) nuclear grade III consisted of the nuclei that were 
irregular and larger than normal (Queiroga et al., 2010).The degree of pigmentation was 
estimated using a subjective scale from scant (pigment in fewer than 30% of cells), moderate 
(pigmentation in 31–80% of cells), and abundant (pigment in more than 80% of cells). The 
amount of stroma was categorized in: scant, moderate, and abundant (Ramos<Vara et al., 
2000). 
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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For immunohistochemical studies, 3<Hm sections were cut from each specimen and 
mounted on silane<coated slides. MAC 387 (for macrophage immunolabelling) and Cox<2 
immunoexpression were carried out by the streptavidin<biotin<peroxidase complex method, 
with a commercial detection system (Ultra Vision Detection System; Lab Vision 
Corporation, Fremont, USA) following the manufacturer’s instructions, with and without 
blanching. Antigen retrieval was by microwave treatment in citrate buffer (pH 6.0) three 
times for 5 min each in a 750 W microwave oven, followed by cooling for 20 min at room 
temperature.  
Primary antibodies were: MAC 387 (AbDSerotec, MorphoSys UK Ltd., Kidlington, 
Oxford,U.K.; Clone MCA 874G) diluted 1 in 100 in PBS and applied for 1 h at room 
temperature and COX<2 (Transduction Laboratories, Lexington, Kentucky; clone 33) diluted 
1 in 40 in phosphate buffered saline (PBS; pH 7.4, 0.01 M) and applied overnight at 4°C. 
Immunoreaction was visualized by incubation with 3,3’<diaminobenzidine 
tetrahydrochloride (DAB) at 0.05% with 0.01% H2O2 as the final substrate for 5 minutes. 
After a final washing in distilled water, the sections were counterstained with haematoxylin, 
dehydrated, cleared and mounted.  
The primary antibody was replaced by PBS and by an irrelevant antibody for negative 














Positivity was indicated by the presence of distinct brown cytoplasmic labeling. 
Immunoreactivity was evaluated ‘‘blindly’’ by two observers (IP e FLQ).  
TAMs were counted in the three regions with more intense and homogeneous positivity of 
each of counting areas (Hussein et al., 2009). In these regions, we counted all labeled cells, 
evaluating a total of ten high<power fields (HPF), (400x magnification power). TAM were 
then categorized in three classes: 1: <20 positive macrophages (sparse); 2: 20<100 (moderate), 
3: >100 positive macrophages (intense) (Piras et al., 2005).  
Positive Cox<2 expression was defined when more than 10% of the tumour cells showed 
positive staining. The staining intensity was not scored in this method. 
 &'
The statistical software SPSS version 12.0 was used for statistical analysis. The Chi<square 
test and the Fisher’s exact test were used for studying categorical variables. In all statistical 
comparisons, p< 0.05 was accepted as denoting significant differences. 
$ (
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
From the 37 tumours included in the study, 8 cases were classified as melanocytomas 
(benign tumours) and 29 cases as malignant melanomas (malignant tumours, Fig.1). 
 
 
Fig. 1. Cutaneous malignant melanoma in a German Shepard dog. 
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MAC 387 immunostaining was always observed in the cytoplasm of macrophages in a 
diffuse and homogeneous pattern. The upper layers of epidermis also stained with MAC 
387. 
TAMs were observed in all the samples analyzed (n=37). As shown in Table 1, all the benign 








moderate or intense infiltration (Fig.2 and Fig.3). The number of tumoural<associated 
macrophages in malignant melanoma was significantly higher than the mean values in the 
benign counterparts (p=0,002).  
 
 




Fig. 3. Intense infiltration of macrophages in a cutaneous melanoma. IHC. Bar, 120 Hm. 
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The expression of COX<2 was absent in 18/37 (48,6%) of the canine melanocytic tumours 









malignant tumours, COX<2 was expressed by 19 of the 29 melanomas (65,5%), (Fig. 5 e Fig. 
6). There was a significant difference in COX<2 expression between melanocytomas and 





Fig. 4. Cutaneous malignant melanoma considered negative to Cox<2 (less than 10% of 




















Table 1 presents the clinicopathological variables analyzed and its association with TAM 
and Cox<2 expression in canine melanocytic tumours.  
The number of TAMs presented a statistical significant association with the presence of 
ulceration (p<0,001), presence of necrosis (0,001), nuclear grade (p=0,046), degree of 
pigmentation (p<0,001), tumoural aberrant cells (p=0,014), stroma (p=0,018) and tumoural 
embolus (p=0,011). Canine melanocytictumours with ulceration, necrosis, with a high 
nuclear grade, less pigmented, with the presence of tumoural aberrant cells, with a scarce or 
moderate stroma and with vascular invasion have a high number of macrophages 
associated to the tumour.  
COX<2 expression was associated with ulceration (p=0,005), necrosis (p=0,003), mitotic index 
(p=0,029), nuclear grade (p=0,035) and degree of pigmentation (p=0,001). Cox<2 expression 
was observed in tumours with epithelium ulceration, necrosis, high mitotic index and 




There was a significant association between the number of TAMs and COX<2 expression in 
canine melanocytic tumours (p=0,006). Cox2 positive tumours had a high number of TAMs. 
Among Cox< negative tumours, only 3 out of 18 tumours had a moderate or abundant 
number of TAMs. Considering only malignant melanomas, in spite of Cox<2 positive 































































































































































































































































































































































































































































Table 2. Association of clinicopathological variables with TAMs and Cox<2 in canine 
malignant melanomas. 
% -
Melanoma is relatively common in dogs, accounting for 3% of all neoplasms and up to 7% of 
all malignant tumours. Melanocytic neoplasms that arise in the oral cavity, one of the most 
frequent localization of melanocytic tumours in dog,  are virtually always considered 
malignant and constitute the most common oral malignant neoplasm (Smith et al., 2002). 
Much work is currently underway in to try and identify specific tumour markers, associated 
with malignancy. However, more studies are needed to differentiating canine benign from 
malignant melanocytic neoplasms or predicting survival times. 
% 
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It has long been thought that inflammation and carcinogenesis are related (Le 









constitute one of the first barriers against infection. Depending on the activation state of the 
macrophage, this antigen presentation may trigger a full<blown active immune response, or 
may suppress a potential immune reaction (Jager et al., 2011). The role of macrophages in 
tumour growth and development is complex and multifaceted. Whilst there is limited 
evidence that TAMs can be directly tumouricidal and stimulate the anti<tumour activity of T 
cells, there is now contrasting evidence that tumour cells are able to block or evade the 
activity of TAMs at the tumour site. In some cases, tumour<derived molecules even redirect 
TAMs activities to promote tumour survival and growth (Bingle et al., 2002). 
In our study, TAMs were observed in all tumours analyzed. Melanocytomas presented few 
macrophages, while malignant melanoma showed generally moderate or intense 
macrophage infiltration. Higher number of TAMs has been associated with malignancy in 
different types of human tumours (Siveen&Kuttan, 2009), as breast carcinomas (Leek et al., 
1996) and gliomas (Nishie et al., 1999). In human cutaneous melanoma (Torisu et al., 2000), 
uveal melanoma (Toivonen et al., 2004) and sinonasal melanoma (Shi et al., 2010) a high 
number of TAMs was closely associated with bad tumour phenotypes. These observations 
were in accordance with our results in canine melanocytic lesions. 
In canine melanocytic tumours, a higher number of TAMs appears associated, in a statistical 
significant way, with ulceration (p<0,001), necrosis (0,001), nuclear grade (p=0,046), degree 
of pigmentation (p<0,001), tumoural aberrant cells (p=0,014), stroma (p=0,018) and tumoural 
embolus (p=0,011). Even considering only malignant melanomas, an association was noted 
between TMAs and ulceration (p=0,016), histological necrosis (p=0,007), degree of 
pigmentation (p=<0,001) and presence of vascular invasion by tumoural cells (p=0,049). 
Interestingly most of these characteristics are classically linked to higher tumoural 
aggressiveness and poor clinical prognosis in these neoplasias. TAMs could constitute an 
important marker of canine melanocytic aggressiveness; however, studies with prognostic 
are needed to clarify this subject.  
The statistical significant association observed between tumoural necrosis and a high 
number of TAMs in malignant melanomas is not surprising. Indeed, in human cancer, 
evidence has emerged for a symbiotic relationship between tumour cells and TAMs. The 
pathways involved in this crosstalk could imply a response to micro<environmental factors 
such as hypoxia, as well as various growth factors and enzymes that stimulate tumour 
angiogenesis (Bingle et al., 2002). Many macrophage products released in the tumour stroma 
can directly stimulate the growth of tumour cells and/or promote tumour cell migration 
and metastasis. These include, for instance, the epidermal growth factor (EGF), cytokines 
like IL<6 and TNF, as well as chemokines such as CXCL12. TAMs contribute to tumour 
progression also by producing several factors which enhance neo<angiogenesis and the 
dissolution and remodeling of the interstitial matrix. Moreover TAMs are a source of potent 
immunosuppressive molecules, such as IL<10 and PGE2, contributing to the tumour 
immune<evasion (Allavena et al., 2008; Mantovani et al., 2002; Van Ginderachter et al., 2006). 
It is probably that similar mechanisms occur also in canine malignant melanomas. 
% 	)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Cox<2 is a key enzyme controlling the conversion of arachidonic acid to prostaglandin H2, 
the precursor of various molecules, including prostaglandins, prostacyclins and 
tromboxanes. Cox<2 is commonly undetectable in normal tissues, but can be induced 
through several stimuli, including mitogens, growth factors, hormones, and cytokines 








explain how increased Cox<2 and the resultant prostaglandin overproduction might 
contribute to carcinogenesis (Hu et al., 2009; Singh<Ranger et al., 2008; Wu&Liou, 2009). 
These pathways included stimulation of tumoural angiogenesis, decreased tumoural 
apoptosis, increased invasion and metastasis, immune suppression and tumour associated 
inflammation (Ghosh et al., 2010). Various studies indicate a link between high Cox<2 
expression and malignancy in both human (Balan et al., 2011; Costa et al., 2002; Lee et al., 
2011) and canine tumours (Queiroga et al., 2007; Queiroga et al., 2010). In the dog, Cox<2 
‘‘up<regulation’’ has been investigated in different tumours, including prostate 
(L'Eplattenier et al., 2007), ovarian (Borzacchiello et al., 2007), bladder (Khan et al., 2000), 
intestinal (McEntee et al., 2002), mammary (Queiroga et al., 2005; Queiroga et al., 2007; Dias 
Pereira et al., 2009), nasal carcinomas (Impellizeri & Esplin, 2008) and sarcomas, including 
osteosarcoma and oral fibrosarcoma (Heller et al., 2005; Mullins et al., 2004). In human 
cancer, Cox<2 expression has been detected in a considerable number of epithelial tumours 
as breast, lung, colon, prostate, head and neck, gastric, ovary, among many others (Ghosh et 
al., 2010; Menczer, 2009; Wu et al., 2010). 
Concerning malignant melanoma, in humans it was recently reported that changes in Cox<2 
expression levels were correlated with development and progression of human melanoma 
(Goulet et al., 2003; Kuzbicki et al., 2006). COX<2 expression arises as a potential 
immunohistochemical marker for distinguishing human cutaneous melanomas from benign 
melanocytic lesions (Minami et al., 2011; Pires et al., 2010). Additionally, Cox<2 expression 
appears as a useful prognostic marker being related with histological and clinical malignant 
melanoma aggressiveness (Becker et al., 2009).  
In canine melanocytic tumours, Cox<2 expression was recently described (Paglia et al., 2009; 
Pires et al., 2010). Cox<2 over<expression was related with a tumoural malignant behavior  
(Pires et al., 2010) and with a poor overall survival (Martínez et al., 2011). In the present 
work, Cox<2 expression was associated with ulceration (p=0,005), necrosis (p=0,003), mitotic 
index (p=0,029), nuclear grade (p=0,035) and degree of pigmentation (p=0,001). These 
associations could represent the higher aggressiveness of Cox<2 positive melanocytic 
tumours. Curiously, these associations lost their statistical significance when we consider for 
statistical analysis only the group of malignant melanomas.  However, an association with 
mitotic index is observed, that suggests that Cox<2 is associated with a higher cellular 
proliferation. The real significance of these results needs to be clarified. Clinical studies, with 
follow<up information and proliferation markers will be necessary to clarify if Cox<2 could 
be more important in early phases of carcinogenesis  or also in tumour progression. 
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Tumour associated macrophages and high COX<2 expression have been both associated 
with malignancy in canine melanocytic tumours, but their potential interdependence has 
not yet been evaluated. The present study showed that there is a close relationship between 
TAMs and Cox<2 expression in canine melanocytic lesions. This is the first time, to our best 
knowledge, that a similar relationship was investigated in tumours of domestic animals. 
This crosstalk is referred in human tumours, as colorectal carcinoma (Naghshvar et al., 
2009), urotelial carcinoma (Chen et al., 2009), basal cell carcinoma (Tjiu et al., 2009) and in 
breast cancer cells (Hou et al., 2011). The pathways involved in this relationship are diverse, 
and remain to be completed elucidated. In human basal cell carcinoma, macrophages 
induced COX<2<dependent release of matrix metalloproteinase<9 and subsequent increased 









vascular endothelial growth factor<A, and increased angiogenesis (Tjiu et al., 2009). 
Macrophage<mediated induction of COX<2 in breast cancer cells is a consequence of IL<1β<
mediated stimulation of ROS→Src→MAP kinase→AP<1 signaling. IL<1β<dependent 
induction of COX<2 in breast cancer cells provides a mechanism whereby macrophages 
contribute to tumour progression (Hou et al., 2011). Another mechanism proposed could 
involve Cox<2 induced angiogenesis through increasing TAM infiltration or hypoxia<
inducible factor<1alpha by hypoxia (Chen et al., 2009).  
Considering only malignant melanomas, the association was not significant that could 
suggested that this cross<talk (between TAMs and Cox<2 positive tumoural cells) could be 
decisive in carcinogenesis but not in tumour progression. Only more studies could help to 
investigate the meaning of these findings. In turn, in human oral squamous cell carcinoma, 
Cox<2 and TAMs are not related (Boas et al., 2010).  
The development of therapeutic targeting of cancer promoting inflammatory reactions is 
crucially dependent on defining the underlying cellular and molecular mechanisms in 
relevant systems (Allavena et al., 2008). By inhibiting the release of prostaglandins from the 
tumour and by blocking COX activity in immune effector cells, NSAIDs may also bias the 
function of immune cells towards a more tumouricidal phenotype (Lang et al., 2006). 
& 
In conclusion, this study presents a close relationship of TAM and Cox<2 expression in 
canine melanocytic lesions. It is possible that proinflammatory cytokines released by 
intratumoural macrophages, up<regulate Cox<2 tumour cells expression stimulating tumour 
progression. Additionally, the differences observed between benign and malignant 
melanocytic lesions may suggest that TAM and Cox<2 are implicated in the progression of 
melanocytic precursor lesions to malignant melanoma. 
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